Myelodysplastic Syndrome Drugs Companies

Celgene Corporation Received FDA approval for luspatercept (Reblozyl) in July 2023 for treating anemia associated with MDS in ring sideroblast-positive patients who have failed erythropoietin-stimulating agents.

Geron Corporation Announced positive results from the Phase 3 IMerge study of imetelstat (Jivi) in lower-risk MDS in November 2023, paving the way for potential FDA approval soon.

Incyte Corporation Expanded the label of ruxolitinib (Jakafi) in December 2023 to include treatment of corticosteroid-refractory acute graft-versus-host disease (GVHD) in patients with MDS or AML who have undergone hematopoietic stem cell transplantation.

Agios Pharmaceuticals Partnered with a leading research institute in January 2024 to develop targeted therapies for high-risk MDS subtypes associated with specific gene mutations.

Jazz Pharmaceuticals Signed a definitive agreement to acquire Epizyme, Inc., a company developing novel EZH2 inhibitors for MDS and other types of cancer, in February 2024. This acquisition further strengthens Jazz's portfolio of MDS treatments.

• Bristol Myers Squibb


• Cipla limited


• Gordon


• Amgen


• BluePoint Laboratories


• Sandoz


• Crystal Genomics Inc.


• Gilead sciences.


• Johnson and Johnson


• Lupin Ltd corporation